Profitable Micro-caps (Revenue greater than $10m)

[percy]

Good result out from AZV. Half year NPAT of $566k from continuing operations on market cap of $8.3m at current sp of 4.4cps. Appears to be a growth forecast and good growth apparent in the North American segment, with more to come after recent contract with Honeywell, Canada.

Good result? No.
It was OUTSTANDING.!!! Well done.

[Joshuatree]

I see a research note on HDX is out with a target of 60c which looks realistically achievable. Nice to see Brokers focusing on this CoalDentist with clients lining up..

[Joshuatree]

also from Baillieu Holst a research note with a blended valn of 71c on HDX. PM me if you want a copy , cheers JT

[percy]

Nearly one million shares traded today.mostly at 5 and 5,2 cents,so market liked the result.A lot of shares for such an illiquid company.

[steve fleming]

ACG has been getting a fair bit of media profile recently, including in the Eureka Report:

AtCor Medical Holdings (ACG)

A more obscure, but stronger, outperformer is blood pressure device maker AtCor.
The stock is so small (market capitalisation of $14 million) it doesn’t qualify to be included in the Small Industrials Index.
But the pocket rocket managed to beat the market by a 28.4% margin in the three days since February 21 when it announced a record interim net profit of $2.3 million compared with a loss of $900,000 for the same time last year.
Atcor has never made such a big profit, even for a full year, and it can thank strong demand for its device from US pharmaceutical and research companies as that bolstered its top line by 43 % to $5.4 million for the six months to end December.
AtCor has developed a better way to measure blood pressure as its non-invasive device also picks up early signs of cardiovascular problems.
While it has been proven countless times that the market doesn’t always want to buy the proverbial “better mouse trap”, especially when it comes to the highly conservative medical fraternity, confidence is growing that AtCor’s strategy to drive market adoption is working.
Management is looking to gain market acceptance for its device by targeting companies running clinical trials, as its technology allows clinicians to study the effects of new drugs on the heart.
If AtCor’s device gains enough traction in the laboratories, it could very well find its way into hospitals and doctors’ rooms.
AtCor is only suited for investors with a tolerance to risk, as it is hard to say what type of penetration rates it can eventually achieve.
But, at this early stage, there is plenty of room to grow given that the addressable market size for the clinical trial industry is estimated at around $100 million a year.
AtCor didn’t give an outlook, but assuming that management can continue to sustain sales momentum, the stock is looking very cheap given that it is trading on a price-earnings multiple of seven times just on its half-year profit number alone.
On the downside though there is little scope for recurring sales as there are no consumables for the device, which looks like an ADSL modem connected to a wrist band.

[Lizard]

I see Pacific Environment Holdings (PEH) has finally achieved a rolling year $10m revenue with the latest result ($6.7m for the half year). They also reported nearly $700k profit. Share price jumped from 3.2cps to 5.0cps for a market cap of $4.9m.

I looked at these a couple of years ago and bought a small number at 10cps! Have tried to average down since, but only ended up catching a few rats and mice due to lack of liquidity. May try to top up again if sellers return. I like the consultancy-style business model in a specialist field where there is likely to be ongoing demand.

Be aware that one director has a convertible note, although terms are not onerous.

[NZSilver]

JT requested i try and post this HDX report - cheers.


Hughes Drilling

[NZSilver]

sorry JT didnt work

[Corporate]

good listen on HDX

http://www.brrmedia.com/event/110421

[Joshuatree]

Yes all good Corp. Also liked the increasing Hydraulics operations.For 6 months rev was 5% and ebitda 10%. Longterm growth target of 25% of operations.
Demand exceeding supply continues....... GROWTH< GROWTH and GROWTH.

Any comments steve? cheers ps new holders continue to appear . ops Thanks NZ SILVER anyway. .If anyone still wants the research report PM me.